00:51 , Aug 2, 2019 |  BC Extra  |  Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the...
00:00 , Apr 26, 2019 |  BC Extra  |  Company News

Management tracks: Canbridge, Averum, WindMIL

Cancer and rare disease company Canbridge Pharmaceuticals Inc. (Beijing, China) hired Glenn Hassan as CFO and CBO and Gerald Cox as chief development strategist and interim CMO. Hassan, who was director, cross border healthcare investment...
17:15 , Apr 5, 2019 |  BC Week In Review  |  Company News

Pierre Fabre gets European, African rights to Puma's Nerlynx

Pierre Fabre will pay $60 million up front for commercialization rights to Puma's Nerlynx neratinib in Europe, excluding Russia and Ukraine, and in certain North and West African countries. Puma Biotechnology Inc. (NASDAQ:PBYI) is also...
13:31 , Feb 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); melanoma Mouse studies suggest inhibiting CD95 could help enhance the efficacy of adoptive T cell therapies for melanoma and ALL. In a mouse model of melanoma, adoptive transfer of T...
17:46 , Jan 11, 2019 |  BC Week In Review  |  Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
20:42 , Jan 8, 2019 |  BC Extra  |  Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
17:08 , Oct 26, 2018 |  BC Week In Review  |  Company News

Canbridge, WuXi team up to develop rare disease therapies in China

Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in China. Canbridge expects to submit its first IND from the program for a rare disease in China...
19:20 , Oct 23, 2018 |  BC Extra  |  Company News

Canbridge, WuXi team up to develop rare disease therapies in China

Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in China. Canbridge expects to submit its first IND from the program for a rare disease in China...
19:57 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Canbridge submits NDA in China for breast cancer drug Nerlynx

Canbridge Life Sciences Ltd. (Beijing, China) said China's National Medical Products Administration (NMPA) accepted an NDA for Nerlynx neratinib as an extended adjuvant treatment for adult patients with early stage HER2-positive breast cancer following adjuvant...